BR0203656A - Uso de estatinas para inibir a formação de osteoclastos - Google Patents
Uso de estatinas para inibir a formação de osteoclastosInfo
- Publication number
- BR0203656A BR0203656A BR0203656-8A BR0203656A BR0203656A BR 0203656 A BR0203656 A BR 0203656A BR 0203656 A BR0203656 A BR 0203656A BR 0203656 A BR0203656 A BR 0203656A
- Authority
- BR
- Brazil
- Prior art keywords
- osteoclast formation
- statin
- statins
- mammal
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DE ESTATINAS PARA INIBIR A FORMAçãO DE OSTEOCLASTOS". Método para inibir a formação de osteoclastos compreendendo a administração de uma quantidade terapeuticamente eficaz de uma estatina a um mamífero que disso necessite assim como composições farmacêuticas, kits para conter tais composições compreendendo uma estatina ou um método para tratar ou evitar um estado de doença selecionado do grupo constituído por: osteoporose, doença de Paget, osteólise, hipercalcemia maligna, osteogênese imperfecta, osteoartrite, perda óssea alveolar, efeitos secundários de terapia imunossupressiva e efeitos secundários do uso glucocorticóide crónica por inibição da formação de osteoclastos compreendendo a administração de uma quantidade terapeuticamente eficaz de uma estatina a um mamífero que disso necessite.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31845001P | 2001-09-10 | 2001-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0203656A true BR0203656A (pt) | 2003-06-03 |
Family
ID=23238236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0203656-8A BR0203656A (pt) | 2001-09-10 | 2002-09-09 | Uso de estatinas para inibir a formação de osteoclastos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20030055101A1 (pt) |
EP (1) | EP1291017A3 (pt) |
JP (1) | JP2003104883A (pt) |
KR (1) | KR20030022725A (pt) |
CN (1) | CN1403081A (pt) |
BR (1) | BR0203656A (pt) |
CA (1) | CA2401319A1 (pt) |
HU (1) | HUP0202969A3 (pt) |
IL (1) | IL151571A0 (pt) |
NZ (1) | NZ521188A (pt) |
PL (1) | PL355958A1 (pt) |
TW (1) | TWI226238B (pt) |
ZA (1) | ZA200207233B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2526730A1 (en) | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives |
EP1761270A1 (en) * | 2004-06-23 | 2007-03-14 | Merck & Co., Inc. | Estrogen receptor modulators |
KR101224256B1 (ko) * | 2005-10-14 | 2013-01-18 | 한양대학교 산학협력단 | 레이저 기반의 이동 단말을 위한 다중채널의 장면구성 제어방법 및 장치 |
SG166829A1 (en) | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
US20110086080A1 (en) * | 2007-11-14 | 2011-04-14 | Osteosphere, Llc | Ex-vivo production of human demineralized bone matrix |
US8506982B2 (en) * | 2007-11-14 | 2013-08-13 | Osteosphere, Llc | Development of a human colloidal bone graft material |
WO2009064917A2 (en) * | 2007-11-14 | 2009-05-22 | Osteosphere, Llc | Generation of an hla-negative osteogenic precursor cell line |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2591782A1 (en) * | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
TWI542569B (zh) * | 2015-02-11 | 2016-07-21 | 高雄醫學大學 | 3,5-二羥基戊酸的類似物用於成骨作用 |
CN109248338A (zh) * | 2018-11-16 | 2019-01-22 | 张浩淼 | 可吸收膜及其制备方法和应用、牙种植体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
WO1999045923A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
US20010025028A1 (en) * | 1998-03-13 | 2001-09-27 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
US6403637B1 (en) * | 1999-08-09 | 2002-06-11 | Univ Saint Louis | Methods of modulating matrix metalloproteinase activity and uses thereof |
WO2001037876A2 (en) * | 1999-11-24 | 2001-05-31 | Bayer Aktiengesellschaft | Methods of ameliorating abnormal bone states |
-
2002
- 2002-08-27 EP EP02019026A patent/EP1291017A3/en not_active Withdrawn
- 2002-09-02 IL IL15157102A patent/IL151571A0/xx unknown
- 2002-09-03 CN CN02132146A patent/CN1403081A/zh active Pending
- 2002-09-04 TW TW091120188A patent/TWI226238B/zh active
- 2002-09-04 NZ NZ521188A patent/NZ521188A/en unknown
- 2002-09-05 CA CA002401319A patent/CA2401319A1/en not_active Abandoned
- 2002-09-09 BR BR0203656-8A patent/BR0203656A/pt not_active IP Right Cessation
- 2002-09-09 ZA ZA200207233A patent/ZA200207233B/xx unknown
- 2002-09-09 HU HU0202969A patent/HUP0202969A3/hu unknown
- 2002-09-10 US US10/238,266 patent/US20030055101A1/en not_active Abandoned
- 2002-09-10 JP JP2002264412A patent/JP2003104883A/ja active Pending
- 2002-09-10 KR KR1020020054503A patent/KR20030022725A/ko not_active Application Discontinuation
- 2002-09-10 PL PL02355958A patent/PL355958A1/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1291017A2 (en) | 2003-03-12 |
KR20030022725A (ko) | 2003-03-17 |
IL151571A0 (en) | 2003-04-10 |
CN1403081A (zh) | 2003-03-19 |
NZ521188A (en) | 2004-06-25 |
US20030055101A1 (en) | 2003-03-20 |
HU0202969D0 (pt) | 2002-10-28 |
EP1291017A3 (en) | 2003-07-02 |
ZA200207233B (en) | 2004-03-09 |
JP2003104883A (ja) | 2003-04-09 |
HUP0202969A3 (en) | 2004-08-30 |
TWI226238B (en) | 2005-01-11 |
HUP0202969A2 (hu) | 2003-07-28 |
PL355958A1 (en) | 2003-03-24 |
CA2401319A1 (en) | 2003-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0203656A (pt) | Uso de estatinas para inibir a formação de osteoclastos | |
BR0211364A (pt) | Composição farmacêutica para tratamento de doenças associadas com redução na massa óssea compreendendo o agonista ep4 como componente ativo | |
BR0115696A (pt) | Uso de bisfosfonatos para tratamento de dor | |
BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
BR9909597A (pt) | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas | |
SE9901272D0 (sv) | New improved formulation | |
BRPI0407375A (pt) | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos | |
EP1430061A4 (en) | INCLUSION COMPOUND CONTAINING CUCURBITURIL DERIVATIVES AS RECEPTOR MOLECULE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
IS5890A (is) | Aðferð til að gefa sýklalyf | |
BRPI0611814A2 (pt) | moduladores parp e tratamento de cÂnceres | |
BR0016058A (pt) | Compostos de fosfonato | |
BRPI0408477A (pt) | compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos | |
GT199700009AA (es) | Terapia combinada para la osteoporosis | |
ES2191475T3 (es) | Conjugados de prostaglandina para el tratamiento o prevencion de enfermedades oseas. | |
BRPI0410669A (pt) | inibidores de caspase e usos dos mesmo | |
BR0105457A (pt) | Combinações terapêuticas para estimulação do crescimento ósseo | |
BR0209128A (pt) | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
BR0208017A (pt) | Combinação compreendendo combretastatina e agentes anticâncer | |
BR0214614A (pt) | Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2 | |
BR0211203A (pt) | Acilsemicarbazidas como inibidores de cinase dependente de ciclina úteis como agentes anti-câncer e anti-proliferativos | |
BR0008603A (pt) | Método para tratamento de copd | |
DK1756046T3 (da) | Arylalkylsulfonamider som terapeutiske midler til behandling af knoglelidelser | |
BR0013416A (pt) | Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado | |
ATE208402T1 (de) | Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren | |
BR0016646A (pt) | Método para tratar um paciente que sofre de dor, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A,5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1980 DE 16/12/2008. |